biotech / news / / NDTV Profit
In a crucial trial, Eli Lilly reported on Thursday, May 21, 2026, that its experimental obesity medication helped patients lose more than 28% of their body weight over the course of a year and a half.
Eli Lilly's retatrutide led to over 28% average weight loss in patients after 18 months.
KEY POINTS
- Over 45% of trial participants lost at least 30% body weight using the highest dose.
- New data shows dysesthesia rates fell to 12.5%, down from 20.9% in earlier results.
- Retatrutide's weight loss efficacy now matches bariatric surgery, surpassing current obesity drugs.
- Eli Lilly expects to introduce retatrutide to the market as early as next year.
COMPANIES
Summarized by Newsio from NDTV Profit. How we summarize →